NewEdge Wealth LLC decreased its stake in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 69.7% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,387 shares of the medical equipment provider’s stock after selling 10,092 shares during the quarter. NewEdge Wealth LLC’s holdings in Boston Scientific were worth $219,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in BSX. Ameritas Advisory Services LLC increased its holdings in Boston Scientific by 8.5% during the first quarter. Ameritas Advisory Services LLC now owns 6,657 shares of the medical equipment provider’s stock worth $340,000 after buying an additional 524 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its stake in shares of Boston Scientific by 3.0% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 139,354 shares of the medical equipment provider’s stock worth $6,972,000 after purchasing an additional 4,049 shares during the last quarter. Illinois Municipal Retirement Fund lifted its stake in Boston Scientific by 14.3% in the 4th quarter. Illinois Municipal Retirement Fund now owns 145,406 shares of the medical equipment provider’s stock valued at $6,728,000 after purchasing an additional 18,216 shares during the last quarter. Daiwa Securities Group Inc. lifted its stake in Boston Scientific by 3.2% in the 4th quarter. Daiwa Securities Group Inc. now owns 136,437 shares of the medical equipment provider’s stock valued at $6,313,000 after purchasing an additional 4,188 shares during the last quarter. Finally, Dubuque Bank & Trust Co. grew its holdings in Boston Scientific by 4.3% during the first quarter. Dubuque Bank & Trust Co. now owns 5,112 shares of the medical equipment provider’s stock worth $256,000 after purchasing an additional 209 shares during the period. Institutional investors and hedge funds own 92.20% of the company’s stock.
Boston Scientific Price Performance
Shares of NYSE BSX opened at $51.03 on Monday. The stock has a market capitalization of $74.72 billion, a PE ratio of 85.05, a P/E/G ratio of 2.00 and a beta of 0.79. Boston Scientific Co. has a fifty-two week low of $37.74 and a fifty-two week high of $54.74. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.29 and a quick ratio of 0.80. The business has a fifty day moving average price of $52.45 and a two-hundred day moving average price of $50.65.
Insider Buying and Selling
In other Boston Scientific news, EVP Wendy Carruthers sold 11,671 shares of the company’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $53.24, for a total transaction of $621,364.04. Following the completion of the sale, the executive vice president now directly owns 72,847 shares in the company, valued at $3,878,374.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Arthur C. Butcher sold 6,697 shares of the stock in a transaction that occurred on Wednesday, June 21st. The shares were sold at an average price of $53.80, for a total value of $360,298.60. Following the completion of the transaction, the executive vice president now owns 17,453 shares of the company’s stock, valued at approximately $938,971.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Wendy Carruthers sold 11,671 shares of the business’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $53.24, for a total transaction of $621,364.04. Following the sale, the executive vice president now directly owns 72,847 shares in the company, valued at approximately $3,878,374.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 93,378 shares of company stock worth $4,993,445. Corporate insiders own 0.71% of the company’s stock.
Analysts Set New Price Targets
BSX has been the subject of a number of recent analyst reports. StockNews.com initiated coverage on Boston Scientific in a research report on Thursday, May 18th. They issued a “buy” rating for the company. Deutsche Bank Aktiengesellschaft raised their price target on Boston Scientific from $45.00 to $55.00 in a report on Thursday, April 27th. CL King began coverage on shares of Boston Scientific in a report on Friday, June 30th. They issued a “buy” rating and a $64.00 price objective on the stock. Canaccord Genuity Group raised their target price on shares of Boston Scientific from $58.00 to $62.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Finally, Oppenheimer lifted their target price on shares of Boston Scientific from $58.00 to $59.00 in a report on Friday, July 28th. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $58.35.
Check Out Our Latest Research Report on Boston Scientific
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Featured Articles
- Five stocks we like better than Boston Scientific
- What is a SEC Filing?
- MarketBeat Week in Review – 8/7 – 8/11
- How to Buy Metaverse Stock Step by Step
- 3 Retailers To Watch Closely Next Week
- How to Find Undervalued Stocks
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
